**CURRICULUM VITAE**

**Naresh Mandava, M.D.**

Sue Anschutz-Rodgers Chair in Retinal Diseases

Professor and Chair

University of Colorado Department of Ophthalmology

Rocky Mountain Lions Eye Institute

1675 Aurora Court, Mailstop F731

Aurora, CO 80045

**Appointments: 720-848-2020**

**PREDOCTORAL EDUCATION:**

**Pre-medical:** Rensselaer Polytechnic Institute, Troy, NY (1986-1990)

B.S., Biological Sciences, *summa cum laude*

6-year BS/MD program

**Medical:** Albany Medical College, Albany, NY (1988-1992)

M.D., *summa cum laude*

**POSTDOCTORAL TRAINING:**

**Internship:** St. Vincent’s Medical Center, Yale University affiliate,

Bridgeport, CT (1992-1993)

**Residency:** Ophthalmology,Manhattan Eye, Ear and Throat Hospital,

New York, NY (1993-1996)

**Fellowships:** Medical and Surgical Vitreoretinal Disease,

Columbia University/ Manhattan Eye, Ear and Throat Hospital,

New York, NY (1996-1998)

Preceptors: Stanley Chang, MD and Lawrence A. Yannuzzi, MD

**MEDICAL SCHOOL APPOINTMENTS:**

1996 – 1998 Clinical Instructor, Department of Ophthalmology,

Harkness Eye Institute, Columbia University, New York, NY

1996 – 1998 Clinical Instructor, Department of Ophthalmology,

Manhattan Eye, Ear & Throat Hospital, New York, NY

1998 – 2004 Assistant Professor, Department of Ophthalmology,

University of Colorado School of Medicine, Aurora, CO

2004 – Associate Professor, Department of Ophthalmology,

University of Colorado School of Medicine, Aurora, CO

2004 – Interim Chair, Department of Ophthalmology,

University of Colorado School of Medicine, Aurora, CO

2007 – Professor, Department of Ophthalmology,

University of Colorado School of Medicine, Aurora, CO

2007 – Chair, Department of Ophthalmology

University of Colorado School of Medicine, Aurora, CO

**HOSPITAL STAFF MEMBERSHIPS:**

1998 – University of Colorado Hospital, Aurora, CO

1998 – Children’s Hospital Colorado, Aurora, CO

1998 – Denver Health Medical Center, Denver, CO

1998 – Veterans’ Administration Hospital, Denver, CO

**HONORS:**

1991 Alpha Omega Alpha (elected junior year), Albany Medical College

1995 Chief Resident (elected), Manhattan Eye, Ear, & Throat Hospital

2004 – 2009 Top Ophthalmologists in America

2007 American Academy of Ophthalmology Honor Award

2008-09, 2012-15 5280 Top Doctors Listing – Metro Denver Listing awarded to three ophthalmologists

2010 Inventor of the Year, University of Colorado Anschutz Medical Campus

**PROFESSIONAL SOCIETIES:**

1991 – Alpha Omega Alpha

1993 – Association for Research in Vision and Ophthalmology

1993 – American Academy of Ophthalmology

2000 – 2006 Pan American Association of Ophthalmology

2001 – American Society of Retina Specialists

2004 – Colorado Society of Eye Physicians and Surgeons

2004 – Colorado Medical Society

2004 – Association of University Professors of Ophthalmology

2005 – Retina Society

2007 – Macula Society

**ADMINISTRATIVE APPOINTMENTS, DEPARTMENT OF OPHTHALMOLOGY, CU:**

1998 – Clinical Committee

1998 – Quality Assurance Committee

1998 – Member, Residency Selection Committee

1998 – Chair, Operating and Procedure Rooms Committee

1998 – Clinical Faculty Promotions Committee

1998 – 2004 Chair, Annual Symposium Committee

1998 – 2004 Chair, Resident, Fellow and Alumni Day Committee

1999 – 2004 Chair, Residency Selection Committee

1999 – 2004 Chair, Grand Rounds Committee

2003 – 2014 Director, Fellowship in Vitreoretinal Diseases and Surgery

2015 – Co-Director, Fellowship in Vitreoretinal Diseases and Surgery

**ADMINISTRATIVE APPOINTMENTS, UNIVERSITY OF COLORADO HOSPITAL:**

2000 – 2010 Operating Room Committee

2004 – Member, Medical Board

2004 – Director, Rocky Mountain Lions Eye Institute

2015 Member, Search Committee, Chief Marketing Officer

**ADMINISTRATIVE APPOINTMENTS, SCHOOL OF MEDICINE, CU:**

2004 – Member, Executive Committee

2014 – 2015 Chair, Anesthesiology Chair Search Committee

**ADMINISTRATIVE APPOINTMENTS, UNIVERSITY PHYSICIANS, INC:**

2004 – Board Member

2014 – Chair, Strategy Committee

**PUBLIC SERVICE:**

2004 – Lions Club of Denver

2004 – Rocky Mountain Lions Eye Institute Foundation

2004 – Member, Rocky Mountain Lions Eye Institute Advisory Board

2012 – 2015 Member, Crestmoor Community Association Board

2016 Member, Board of Trustees of the Denver Museum of Nature and Science

**SPECIALTY BOARD CERTIFICATION:**

1997 Diplomat, American Board of Ophthalmology

(99th percentile ABO exam)

**LICENSES:** 1993 – State of New York (inactive)

1998 – State of Colorado

**REVIEWER:** Archives of Ophthalmology/JAMA

British Journal of Ophthalmology

Fight for Sight, Grant Reviewer

Investigative Ophthalmology and Visual Science

Ophthalmic Surgery and Lasers

Ophthalmology

Research to Prevent Blindness, Advisory Council

Retina

**RESEARCH SUPPORT AND GRANTS:**

1. **Second Sight Medical Products**, PM-02-01, Mandava (PI): “New Enrollment Post-Approval Study of the Argus II Retinal Prosthesis System”, Principal Investigator, 2014-2018.
2. **Hoffmann-La Roche**, GX29185, Horning (PI): A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study of Efficacy and Safety of 10 mg Lampalizumab Intravitreal Injections Administered every 30 or 45 Days to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI), Co-Investigator, 2014-2017.
3. **Ophthotech Corporation**, OPH1004, Mandava (PI): “A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin or Eylea Compared to Avastin or Eylea Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration”, Principal Investigator, 2014-2016.
4. **University of Colorado**, 15-1490, Mandava (PI): “OCT Angiography for Ocular Conditions”, Principal Investigator, 2014-2016.
5. **Ophthotech Corporation**, OPH1002/3, Mandava (PI): “A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration”, Principal Investigator, 2013-2016.
6. **Regeneron**, 12-1526, Kahook (PI): “Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma”, Co-Investigator, 2012-2017.
7. **University of Colorado**, 12-0497, Mandava (PI): “Aflibercept for multi-treated choroidal neovascularization with poor clinical response”, Principal Investigator, 2012-2013.
8. **Ophthotech Corporation**, OPH1001, Mandava (PI): “A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration”, Principal Investigator, 2010-2012.
9. **Genentech, Inc.**, FVF4166g, Rubio (PI): “A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion”, Co-Principal Investigator, 2010-2012.
10. **Genentech, Inc.**, FVF4579g, GX01511: “A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)”, Co-Investigator, 2009-2012.
11. **Genentech, Inc**., FVF4170g, Ehrlich (PI): “A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus”, Co-Investigator, 2007-2012.
12. **Regeneron Pharmaceuticals & Bayer**, VGFT-OD-0605, Vitti (PI): “A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration”, Co-Investigator, 2007-2011.
13. **Genentech, Inc.**, FVF3426g, Tuomi (PI): “An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study (HORIZON)”, Co-Investigator, 2006-2011.
14. **ThromboGenics**, TG-MV-006/7: “A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion (MIVI-TRUST)”, Co-Investigator, 2008-2010.
15. **Genentech Corporation**, FVF4165g, Rubio (PI): “A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion”, Co-Principal Investigator, 2007-2009.
16. **Genentech, Inc. & University of Colorado**, FVF4256s, Mandava (PI): “A phase I/II study assessing the safety and efficacy of ranibizumab for non-arteritic ischemic optic neuropathy (NAION)”, Principal Investigator, $174,976, 2007-2009.
17. **National Eye Institute**, U10 EY14231: “A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema”, Co-Investigator, $66,400, 2004-2009.
18. **Alcon Research**, C-02-60, Zilliox (PI): “An evaluation of efficacy and safety of posterior juxtascleral administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD)”, Co-Principal Investigator, $205,000, 2004-2009.
19. **Eyetech Pharmaceuticals & Pfizer**, EOP1023, Mandava (PI): “A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement”, $119,246, Principal Investigator, 2006-2007.
20. **NIH SBIR & Motility, Inc.**, 1R43EY019592-01, Levin (PI): “Motility molecule for treatment of proliferative vitreoretinopathy”, Collaborating Research Scientist, $68,000, 2005-2006.
21. **Alcon Research**, C-04-18: “Clinical Evaluation of the Safety of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus for Use During Surgery for Removal of Epimacular Membrane and Vitrectomy”, Co- Investigator, $37,800, 2005-2006.
22. **Immusol Inc.**, IM-VIT 100-01: “A multi-center, randomized, double-masked placebo controlled study of the safety and efficacy assessment of chimeric ribozyme to PCNA to prevent recurrence of proliferative vitreoretinopathy”, Chairman of Study Design & Medical Monitor, 2002-2004.
23. **Salud Family Center & American Diabetes Association**, Farley (PI): “Screening for diabetic retinopathy by primary care providers”, Consultant, 2002-2004.
24. **Pfizer Inc.**, A1481140, Mandava (PI): “A Multinational, Multi-centre, Randomised, Double-blind, Double-dummy, Placebo-controlled Study to Assess the Efficacy and Safety of 20, 40, and 80mg TID Sildenafil in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over”, Co-Investigator, 2002-2003.
25. **Advanced Corneal Systems Inc.**, VIT-03-08961X, Grillone (PI): “Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage”, Co-Principal Investigator, $5,359, 1999-2003.
26. **Miravant/Pharmacia**, Mandava (PI): “A multi-center, randomized, double-masked, placebo-controlled parallel group study of tin ethyl etiopurpurin (SnET2) photodynamic therapy in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration”, Principal Investigator, $244,935, 1998-2003.
27. **NIH SBIR & Immusol, Inc.**, R44 EY12743, Robbins (PI): “Rabbit PVR model studies”, Co-Investigator, $44,199, 2001-2002.
28. **Eyetech Pharmaceuticals, Inc.**, EOP1004, Mandava (PI): “Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD)”, Principal Investigator, $81,500, 2001-2002.
29. **NIH & UCHSC**, NIH2530687, Spitzer (PI): “A comprehensive human atlas of the body: Human Atlas C”, Investigator for Ophthalmic Portion, 2001-2002.
30. **NIH SIBR & Immusol, Inc.**, R43 EY12743, Robbins (PI): “Chimeric ribozyme for treatment of proliferative vitreoretinopathy”, Collaborating Research Scientist, $27,737, 1999.

**INTELLECTUAL PROPERTY:**

1. Kahook MY, **Mandava N**, Shandas R, Rech B., inventors. The Regents of the University of Colorado, assignee. IMPLANTS FOR REDUCING INTRAOCULAR PRESSURE. US 20120203160. 2010 October 12.
2. Ammar D, Kahook MY, Lei T, Gibson E, Masihzadeh O, **Mandava N**., inventors. The Regents of the University of Colorado, assignee. MULTI-PHOTON TISSUE IMAGING. US 20130149734. 2011 May 31.
3. Shandas R, Lanning CJ, Yeon Glang RG, Rech BA, **Mandava N**, Kahook MY, **Mandava N**., inventors. The Regents of the University of Colorado, assignee. MEDICAL FABRIC WITH INTEGRATED SHAPE MEMORY POLYMER. US 20130218178. 2011 September 12.
4. Kahook MY, **Mandava N**, Shandas R, Rech B., inventors. The Regents of the University of Colorado, assignee. AQUEOUS HUMOR MICRO-BYPASS SHUNTS. US 20130267887. US 20130267887. 2011 September 21.
5. Kahook MY, **Mandava N**, Shandas R, Rech B., inventors. The Regents of the University of Colorado, assignee. IMPLANTATION OF SHAPE MEMORY POLYMER INTRAOCULAR DEVICES. US 20120232648. 2012 April 06.
6. Kahook MY, **Mandava N**, McLean P, Atkinson RE., inventors. The Regents of the University of Colorado, assignee. MODULAR INTRAOCULAR LENS DESIGNS AND METHODS. US 20130190868. 2013 January 23.
7. Kahook MY, **Mandava N**, Shandas R, Rech B., inventors. The Regents of the University of Colorado, assignee. SHAPE MEMORY POLYMER INTRAOCULAR LENSES. US 8685089 B2. 2014 April 01.
8. Olson JL, **Mandava N**., inventors. The Regents of the University of Colorado, assignee. METHOD FOR STIMULATING RETINAL RESPONSE USING PHOTOACTIVE DEVICES. US 8725266 B2. 2014 May 13.
9. Lyons MB, Trommeter JM, **Mandava N**, Kahook MY, Shandas R, Fogelberg J, Castleberry JP., inventors. Endoshape, Inc., The Regents of the University of Colorado, A Body Corporate, assignee. RELIABLY RETAINED SHAPE MEMORY OPHTHALMOLOGICAL IMPLANTS. US 8911495 B2. 2014 December 16.

**PUBLICATIONS: Peer reviewed:**

1. **Mandava N**, Simon JW, Jenkins PL. Preferential looking and recognition acuities in clinical amblyopia. J Ped Ophthalmol Strab 1991;28:323-6.
2. **Mandava N**, Donnenfeld ED, Owens PL, Kelly SE, Haight DH. Ocular deviation following excimer laser photorefractive keratectomy. J Cat Ref Surg 1996;22:504-5.
3. **Mandava N**, Guyer D, Yannuzzi LA, Slakter J, Sorenson J, Spaide RF, Freund KB, Orlock DA. Indocyanine green videoangiography-guided laser photocoagulation of occult choroidal neovascularization. Ophthalmic Surg Lasers 1997;28:844-52.
4. Fisher Y, Hanutsaha P, Tong S, Fenster A, Mazarin G, **Mandava N.** Three- dimensional ophthalmic contact B-scan ultrasonography of the posterior segment. Retina 1998;18:251-6.
5. Schiff W, Chang S, **Mandava N**, Barile GR. Pars plana vitrectomy for persistent, visually significant vitreous opacities. Retina 2000;20:591-6.
6. Bartlett H, Willoughby B, **Mandava N.** Polypoidal choroidal vasculopathy in a patient with melanocytoma of the optic nerve. Retina 2001;21:396-9.
7. Kouyomdjian G, Larkin T, Blackburn P, **Mandava N.** Optic disk edema as a presentation of Propionibacterium acnes endophthalmitis. Am J Ophthalmol 2001;132:259-61.
8. **Mandava N**, Blackburn P, Paul DB, Wilson MW, Read SB, Alspaugh E, Tritz R, Barber JR, Robbins JM, Kruse CA. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2002;43:3338-48.
9. Maberley D, Morris A, Hay D, Chang A, Hall L, **Mandava N**. A comparison of digital retinal image quality among photographers with different levels of training using a non-mydriatic fundus camera. Ophthalmic Epidemiology 2004; 11(3):191-7.
10. **Mandava N**, Costakos D, Bartlett HM. Chronic myelogenous leukemia manifested as bilateral proliferative retinopathy. Arch Ophthalmol 2005; 123(4):576-7.
11. Olson JL, **Mandava N**. Macular hole formation associated with idiopathic parafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2005; 20:1-2.
12. Gelston CD, **Mandava N**, Durairaj VD. Orbital foreign body masquerading as conjunctival melanoma 60 years after injury. Clinical and Experimental Ophthalmology 2005;33(6):661-63.
13. Olson JL, On AV, **Mandava N**. Protecting the retinal pigment epithelium during macular hole surgery. Clinical and Experimental Ophthalmology 2005;33(6): 576-77.
14. Kahook MY, Olson JL, **Mandava N**. Long term follow-up of intraocular pressure elevation in patients post intravitreal triamcinolone acetonide injection. Vision Pan- America 2005;4:9-11.
15. Olson JL, **Mandava N**. Bilateral intraocular involvement in a patient with Lemierre’s syndrome. Br J Ophthalmol 2006;90(2):249-50.
16. **Mandava N**, Kahook MY, Mackenzie DL, Olson JL. Anterior scleral buckling procedure for cyclodialysis cleft with chronic hypotony. Ophthalmic Surgery Lasers Imaging 2006;37(2):151-53.
17. Kahook MY, **Mandava N**, Bateman JB, Thomas JA. Glycosylation type Ic disorder: idiopathic intracranial hypertension and retinal degeneration. Br J Ophthalmol 2006; 90(1):115-116.
18. Gelston CD, Olson JL, **Mandava N**. Macular oedema in central retinal vein occlusion treated with intravitreal triamcinolone. Acta Ophthalmol Scand 2006;84(3):314-18.
19. **Mandava N**, Bartlett HM. Diagnostic and Therapeutic Challenges. Retina 2006;26(2):214-18.
20. Levi ME, **Mandava N**, Chan LK, Weinberg A, Olson JL. Treatment of multi-drug resistant cytomegalovirus retinitis with systemically administered leflunomide. Transplant Infectious Disease. 2006;8(1):38-43.
21. Rudometkin N, Deane K, Olson JL, **Mandava N**. Infliximab in uveitis treatment (Letter to the editor). Archives of Ophthalmology. 2006;124(8):1211.
22. Prall RF, Drack A, Taylor M, Ku L, Olson JL, Gregory D, Mestroni L, **Mandava N**. Ophthalmic Manifestations of Danon Disease. Ophthalmology. 2006;113(6):1010-13.
23. Oliver SC, **Mandava N**. Ultrasonographic signs in complete optic nerve avulsion. Archives of Ophthalmology 2007;125(5):716.
24. Olson JL, Bennett JL, **Mandava N**. Photo Essay: Cerebellar and retinal vascular lesions in a postpartum patient. American Family Physician 2007;75(3):393-4.
25. Kullman G, **Mandava N**, Bennett JL, Kahook MY. Nutritional deficiencies: ocular side effects and visual field defects. Glaucoma Today.
26. Olson JL, Courtney RJ, **Mandava N**. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007;125(9):1221-4.
27. Curtis TH, **Mandava N**. Acute retinal necrosis as a late sequelae of herpes simplex type 1 encephalitis in a child. J AAPOS 2007;11(5):509-10.
28. Schiff WM, Hwang JC, Ober MD, Olson JL, Dhrami-Gavazi E, Barile GR, Chang S, **Mandava N**. A safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol 2007;125(9):1161-7.
29. Taylor MR, Ku L, Slavov D, Cavanaugh J, Boucek M, Zhu X, Graw S, Carniel E, Barnes C, Quan D, Prall R, Lovell MA, Mierau G, Ruegg P, **Mandava N**, Bristow MR, Towbin JA, Mestroni L; Familial Cardiomyopathy Registry. Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet 2007;52(10):830-5.
30. Bennett JL, Thomas S, Olson JL, **Mandava N**. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. Journal of Neuro-Ophthalmology. 2007;27(3):238-40.
31. Farley TF, **Mandava N**, Prall FR, Carsky C. Accuracy of primary care clinicians in screening for diabetic retinopathy using single-image retinal photography. Ann Fam Med. 2008;6(5):428–434.
32. Gohel PS, **Mandava N**, Olson JL, Durairaj VD. Age-related macular degeneration: an update on treatment. Am J Med. 2008;121(4):279-81.
33. Prall RF, Ciardella A, Olson, JL, **Mandava N**. Natural history of macular hole associated with electrical injury: an OCT study. Pan American. 2008.
34. Athappilly G, Pelak VS, **Mandava N**, Bennett JL: Ischemic optic neuropathy, Neurol Res, 30:794-800, 2008.
35. Olson JL, Rouhani B., **Mandava N**. Sub-Tenon’s Triamcinolone for Purtscher’s-like Retinopathy. Clinical Ophthalmology. 2008:2(1) 195-198.
36. Olson JL, Courtney RJ, Rouhani B, **Mandava N**, Dinarello CA. Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model. Ocul Immunol Inflamm. 2009;17(3):195-200.
37. Dixon JA, Oliver SC, Olson JL, **Mandava N**. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18(10):1573-80. Review.
38. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, **Mandava N**. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009;40(3):293-5.
39. Tenku KE, Kahook MY, Barnett CJ, **Mandava N**, Oliver SC. An overview of the retina module of the Heidelberg Retina Tomograph 3. Retina Today. May-June. 2009;4(4)72-75.
40. Kunjukunju N, Navarro A, Oliver SC, Olson JL, Patel CC, Garcia G, **Mandava N**, Quiroz- Mercado H. Bilateral macular hole formation secondary to sclopetaria caused by shockwaves transmitted by a posterior vector: a case report. BMC Ophthalmol. 2010:19;10:6.
41. Kahook MY, Liu L, Ruzycki P, **Mandava N**, Carpenter JF, Petrash JM, Ammar DA. High molecular weight aggregates in repackaged bevacizumab. Retina. 2010:30(6)887-92.
42. Sniegowski M, **Mandava N**, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J. 2010 Jun 22;4:28-9.
43. Horsley MB, **Mandava N**, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010 Jul 17.
44. Ratra D, Uparkar M, Bernstein PS, Simaraman K, Tabin G, **Mandava N**, Lipson BK. Diagnostic And Therapeutic Challenges. Retina. 2010 Jul 30.
45. Good TJ, Kimura AE, **Mandava N**, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2010 Aug 11.
46. Horsley MB, **Mandava N**, Maycotte MA, Kahook MY. Related citations Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010 Oct;150(4):558-561.e1.
47. McCourt EA, Cadena BC, Barnett CJ, Ciardella AP, **Mandava N**, Kahook MY. Measurement of subfoveal choroidal thickness using spectral domain optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec;41 Suppl:S28-33.
48. McCourt EA, Cadena BC, Barnett CJ, Ciardella AP, **Mandava N**, Kahook MY. Measurement of subfoveal choroidal thickness using spectral domain optical coherence tomography.Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec;41.
49. Seibold LK, **Mandava N**, Kahook MY. Comparison of retinal nerve fiber layer thickness in normal eyes using time-domain and spectral-domain optical coherence tomography. Am J Ophthalmol. 2010 Dec;150(6):807-14.
50. Patel CC, Grinblatt A, Korotkin A, **Mandava N**, Oliver SC, Olson JL, Quiroz-Mercado HQ. A novel vitreoretinal dissector for use in vitrectomy. Retina. 2011 Jan;31(1):188-9.
51. Liu L, Ammar DA, Ross LA, **Mandava N**, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011 Feb 22;52(2):1023-34.
52. Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado HQ, **Mandava N**, Olson JL. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2011 Jun;27(3):219-24.
53. Good TJ, Kimura AE, **Mandava N**, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011 Aug;95(8):1111-4.
54. Ernst BJ, García-Aguirre G, Oliver SC, Olson JL, **Mandava N**, Quiroz-Mercado HQ. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy. Acta Ophthalmol. 2012 Mar 9.
55. Patel CC, **Mandava N**, Oliver SC, Braverman R, Quiroz-Mercado HQ, Olson JL. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). Retina. 2012 Mar;32(3): 537-42.
56. Mathias MT, Nagel MA, Khmeleva N, Boyer PJ, Choe A, Durairaj VD, Bennett JL, **Mandava N**, Gilden D. VZV multifocal vasculopathy with ischemic optic neuropathy, acute retinal necrosis and temporal artery infection in the absence of zoster rash. J Neurol Sci. 2013 Feb 15;325(1-2):180-2. PubMed PMID: 23312850.
57. Bhandari R, Ernst BJ, Stafeeva K, **Mandava N**, Quiroz-Mercado HQ. 23-gauge vitrectomy for retained lens material. Ophthalmic Surg Lasers Imaging. 2012 Jul 1;43(4):351-2.
58. Olson JL, Velez-Montoya R, **Mandava N**, Stoldt CR. Intravitreal silicon-based quantum dots as neuroprotective factors in a model of retinal photoreceptor degeneration. Invest Ophthalmol Vis Sci. 2012 Aug 17;53(9):5713-21.
59. Ernst BJ, García-Aguirre G, Oliver SC, Olson JL, **Mandava N**, Quiroz-Mercado HQ. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy. Acta Ophthalmol. 2012 Nov;90(7).
60. Velez-Montoya R, Oliver SC, Olson JL, Fine SL, **Mandava N**, Quiroz-Mercado HQ. Current Knowledge and Trends in Age-Related Macular Degeneration: Today's and Future Treatments. Retina. 2012 Dec 5.
61. Ammar DA, **Mandava N**, Kahook MY.J Neurol Sci. 2013 Feb 15;325(1-2):180-2. doi: 10.1016/j.jns.2012.12.021. The effects of Aflibercept on the Viability and Metabolism of Ocular Cells In Vitro. Retina. 2012 Dec 21.
62. Olson JL, Velez-Montoya R, **Mandava N**, Stoldt CR. Neuroprotective Effect of Photoactive Quantum Dots in Progressive Retinal Photoreceptor Degeneration.J Nanomater Mol Nanotechnol 2013, 2:4
63. Olson JL, Velez-Montoya R, Nghiem N, Ammar DA, **Mandava N**, Stoldt CR. Intraocular Biocompatibility of Gold-Nanoparticles J. Nanomater Mol Nanotech 2013, 2:2.
64. Dunn JH, Weinberg A, Chan LK, **Mandava N**, Levi ME, Olson JL. Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. JAMA Ophthalmol. 2013 Jul;131(7):958-60
65. Velez-Montoya R, Patel CC, Oliver SC, Quiroz-Mercado HQ, **Mandava N**, Olson JL. Intraocular Microsurgical Forceps (20, 23, and 25 gauge) Membrane Peeling Forces Assessment. J Ophthalmol. 2013;2013:784172
66. Gustave BW, Oliver SC, Mathias MT, Velez-Montoya R, Quiroz-Mercado HQ, Olson JL, **Mandava N**, Bhandari R. Reversal of paracentral occlusive retinopathy in a case of sickle cell disease using exchange transfusion. Ophthalmic Surg Lasers Imaging Retina. 2013 Sep-Oct;44(5):505-7
67. Bhandari R, Dacey M, Schwartz S, Olson JL, Quiroz-Mercado HQ, **Mandava N**, Oliver SC. Vogt-Koyanagi-Harada disease masquerading as a lymphoproliferative process of the uvea. Br J Ophthalmol. 2013 Nov;97(11):1482- 3, 1489-90.
68. Block E, Greco M, Vitek D, Masihzadeh O, Ammar DA, Kahook MY, **Mandava N**, Durfee C, Squier J. Simultaneous spatial and temporal focusing for tissue ablation. Biomedical Optics Express. 2013 May 8;4(6):831-41.
69. Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Quiroz-Mercado HQ, **Mandava N**. Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention. Retina. 2014 Mar;34(3):423-41.
70. Olson JL, Wei LA, Fortin MJ, Oliver SC, Quiroz-Mercado HQ, **Mandava N**, Korotkin A. Performance characteristics of a straight versus bent 25-gauge vitrector. Ophthalmic Surg Lasers Imaging Retina. 2014 Mar 1;45(2):153-5.
71. Salcedo-Villanueva G, Harasawa M, Velez-Montoya R, Mathias MT, Siringo FS, Olson JL, Oliver SC, **Mandava N**, Quiroz-Mercado HQ. Spectral Domain Optical Coherence Tomographic Analysis of Healthy Retina in Branch Retinal Vein Occlusion and its response to anti-angiogenic therapy. Retina. 2014 Oct 13.
72. Salcedo-Villanueva G, Paciuc-Beja M, Harasawa M, Velez-Montoya R, Olson JL, Oliver SC, **Mandava N**, Quiroz- Mercado H. Identification and biometry of horizontal extraocular muscle tendons using optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2014 Dec 3.
73. Schwartz S, Gonzalez CL, Bhandari R, Oliver SC, **Mandava N**, Quiroz-Mercado HQ. Retina evaluation with nonmydriatic ultrawide-field color imaging after cataract extraction surgeries in asymptomatic patients. Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):50-5. PubMed PMID: [25559509](http://www.ncbi.nlm.nih.gov/pubmed/25559509/).
74. Salcedo-Villanueva G, Paciuc-Beja M, Harasawa M, Velez-Montoya R, Olson JL, Oliver SC, **Mandava N**, Quiroz-Mercado HQ. Identification and biometry of horizontal extraocular muscle tendons using optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):477-85. PubMed PMID: [25467758](http://www.ncbi.nlm.nih.gov/pubmed/25467758/).
75. Kim YC, Harasawa M, Salcedo-Villanueva G, Siringo FS, Paciuc-Beja M, Olson JL, **Mandava N**, Quiroz-Mercado HQ. Enhanced High-Density Line Spectral-Domain Optical Coherence Tomography Imaging of the Vitreoretinal Interface: Description of Selected Cases. Semin Ophthalmol. 2015 Mar 9:1-8.
76. Schwartz S, Harasawa M, Baldivieso V, Sabel AL, **Mandava N**, Quiroz-Mercado HQ. Nonmydriatic fundus camera for diabetic retinopathy screening in a safety net hospital: effectiveness, prevalence, and risk factors. Eur J Ophthalmol. 2015 Mar-Apr;25(2):145-52. PubMed PMID: [25264120](http://www.ncbi.nlm.nih.gov/pubmed/25264120/).
77. Salcedo-Villanueva G, Harasawa M, Velez-Montoya R, Mathias MT, Siringo FS, Olson JL, Oliver SC, **Mandava N**, Quiroz-Mercado HQ. Spectral domain optical coherence tomographic analysis of healthy retina in branch retinal vein occlusion and its response to antiangiogenic therapy. Retina. 2015 Apr;35(4):704-14. PubMed PMID: [25313712](http://www.ncbi.nlm.nih.gov/pubmed/25313712/).
78. Salcedo-Villanueva G, Paciuc-Beja M, Villanueva-Mendoza C, Harasawa M, Smith JM, Velez-Montoya R, Olson JL, Oliver SC, **Mandava N**, Quiroz-Mercado HQ. Progression of gyrate atrophy measured with ultra-wide-field imaging. Int Ophthalmol. 2015 May 26.
79. Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer PJ, Grose C, Carpenter JE, Rempel A, Bos N, Kandasamy B, Lear-Kaul K, Holmes DB, Bennett JL, Cohrs RJ, Mahalingam R, **Mandava N**, Eberhart CG, Bockelman B, Poppiti RJ, Tamhankar MA, Fogt F, Amato M, Wood E, Durairaj V, Rasmussen S, Petursdottir V, Pollak L, Mendlovic S, Chatelain D, Keyvani K, Brueck W, Nagel MA. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015 May 12;84(19):1948-55. PubMed PMID: [25695965](http://www.ncbi.nlm.nih.gov/pubmed/25695965/).
80. Smith JM, Mathias MT, Oliver SC, **Mandava N**, Olson JL, Quiroz-Mercado HQ, Palestine AG. The influence of needle gauge and infection source on vitreous aspirate cultures. Br J Ophthalmol. 2015 Aug 12;PubMed PMID: [26269533](http://www.ncbi.nlm.nih.gov/pubmed/26269533/).
81. Kim YC, Harasawa M, Salcedo-Villanueva G, Siringo FS, Paciuc-Beja M, Olson JL, **Mandava N**, Quiroz-Mercado HQ. Enhanced High-Density Line Spectral-Domain Optical Coherence Tomography Imaging of the Vitreoretinal Interface: Description of Selected Cases. Semin Ophthalmol. 2015 Aug 21; PubMed PMID: [25751634](http://www.ncbi.nlm.nih.gov/pubmed/25751634/).
82. Salcedo-Villanueva G, Paciuc-Beja M, Villanueva-Mendoza C, Harasawa M, Smith JM, Velez-Montoya R, Olson JL, Oliver SC, **Mandava N**, Quiroz-Mercado HQ. Progression of gyrate atrophy measured with ultra-wide-field imaging. Int Ophthalmol. 2016 Feb;36(1):111-20. PubMed PMID: [26003990](http://www.ncbi.nlm.nih.gov/pubmed/26003990/).

**Clinical trial group publications:**

1. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-16. **Mandava N** (Prinicipal Investigator).
2. Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005;25(7):815-27. **Mandava N** (Principal Investigator).
3. Larsen M, Sander B, Villumsen JE, Haamann PH, la Cour M, Lund-Andersen H; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. [Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication] Ugeskr Laeger 2005;167(35):3301-5. **Mandava N** (Principal Investigator).
4. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140(4):585-97. **Mandava N** (Principal Investigator).
5. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140(4):573-84. **Mandava N** (Principal Investigator).

**CHAPTERS/REVIEWS: (Invited)**

1. **Mandava, N**, Guyer DR. Fluorescein angiography. In: M Yanoff, JS Duker, editors. Ophthalmology. London: Mosby, 1997.
2. **Mandava N**, Fisher Y. Surgical retina. In: Mandava S, Sweeney T, Guyer DR, editors. MEETH Pocket Atlas. New York: Thieme, 1997.
3. **Mandava N**, Guyer DR, Yannuzzi LA, Nichol J, Orlock D. Principles of fluorescein angiography. In: LA Yannuzzi, DR Guyer, S Chang, J Shields, WR Green, editors. Retina, Vitreous, Macula: A Comprehensive Text, 29-38. Philadelphia: WB Saunders, 1999.
4. **Mandava N**, Yannuzzi LA. Coats' disease. In: LA Yannuzzi, DR Guyer, S Chang, J Shields, WR Green, editors. Retina, Vitreous, Macula: A Comprehensive Text, 390-7. Philadelphia: WB Saunders, 1999.
5. Anagnoste S, **Mandava N,** Guyer DR, Yannuzzi LA. Fundus angiography. In: GC Brown, HW Flynn, CD Regillo, editors. Essentials of Vitreoretinal Surgery, 51-64. New York: Thieme, 1999.
6. **Mandava N**, Yannuzzi LA. Miscellaneous retinal vascular diseases. In: GC Brown, HW Flynn, CD Regillo, editors. Essentials of Vitreoretinal Surgery, 193-212. New York: Thieme, 1999.
7. **Mandava N**, Guyer DR, Yannuzzi LA, Reichel E. Fluorescein and ICG angiography. In: M Yanoff, JS Duker, editors. Ophthalmology. London: Mosby, 2002.
8. **Mandava N.** Pharmacologic treatment to inhibit reproliferation in PVR. Vitreoretinal Surgery and Technology 2003;12:1-5.
9. **Mandava N**, Iranmanesh R, Olson JL. Idiopathic perifoveal telangiectasis. In Huang D, Kaiser P, Lowder C, Traboulsi E, editors. Atlas of posterior segment imaging. London: Mosby 2004.
10. **Mandava N**, Olson JL. Fluorescein angiography. In: Huang D, Kaiser P, Lowder C, Traboulsi E, editors. Atlas of posterior segment imaging. London: Mosby 2004.
11. Olson JL**, Mandava N**. Fluorescein and ICG angiography. In: M Yanoff, JS Duker, editors. Ophthalmology. London: Mosby, 2006.
12. Bennett JL, **Mandava N**. Nonarteritic ischemic optic neuropathy, 2008.
13. Prall R, Olson JL, Barnett CJ, **Mandava N**. Fluorescein angiography, Indocyanine green angiography CT, and Optical coherence tomography. In: M Yanoff, JS Duker, editors. Ophthalmology. London: Mosby 2009.
14. Patel CC, Oliver SC, **Mandava N**, Olson JL, Quiroz-Mercado HQ. Implications of the Off-Label Use of Medications in Vitreoretinal Surgery. Quiroz-Mercado HQ, Kerrison JB, et al, editors. Macular Surgery, 2nd edition. Philadelphia: Wolters Kluwer, 2011.
15. Velez-Montoya R, Olson JL, **Mandava N**. Part 6: Retina and Vitreous. Section 3: Ancillary Tests. Chapter 6.8: Fluorescein Angiography and Indocyanine Green Angiography. Yanoff & Duker, Ophthalmology, fourth edition Elsevier, 2012.
16. Patel CC, Olson JL, **Mandava N**, Oliver SCN. Granulomatous uveitis. Maguire JI, Murchison AP, Jaeger EA, ed. *Wills Eye Institute 5-Minute Ophthalmology Consult.* Philadelphia: Wolters Kluwer, 2012.
17. Olson JL, **Mandava N**. Fluorescein Angiography & Indocyanine Green Angiography. M Yanoff, JS Duker, editors. Ophthalmology. London, Mosby. 2013.

**RESEARCH PRESENTATIONS: (Competitive)**

1. Preferential looking and recognition acuities in clinical amblyopia. **Mandava N,** Simon JW, Oral Presentation, Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus 1991.
2. A comparison of astigmatism after penetrating keratoplasty using two suction trephination techniques. **Mandava N**, Lazzaro D, Belmont SC, Yu J. ARVO, Ft. Lauderdale, FL May 1995.
3. Intravitreal and aqueous ofloxacin levels after cataract extraction in rabbits receiving preoperative ofloxacin. **Mandava N**, Grossman, G, Donnenfeld, E. Oral presentation, Grossman, G. Ocular Microbiology and Immunology Group Annual Meeting, Atlanta, GA October 1995.
4. Prophylactic topical antibiotics in cataract surgery: a rabbit endophthalmitis model. **Mandava N**, Donnenfeld E, Grossman G, Mandava S. Ocular Microbiology and Immunology Group at American Academy of Ophthalmology Annual Meeting, Atlanta, GA October 1995.
5. Surgical results and visual outcomes: following sulcus fixation of posterior chamber intraocular lenses. **Mandava N**, Chang S, Schiff W, Reppucci V. Vitreous Society Annual Meeting, New Orleans, LA September 1997.
6. Chimeric ribozyme targeting proliferating cell nuclear antigen (PCNA) prevents retinal detachment (RD) in the rabbit model of proliferative vitreoretinopathy (PVR). **Mandava N,** Blackburn P, Wilson MW, Paul DB, Alspaugh E, Whiting C, Barber JR, Robbins JM, Broswick BM, Kruse CA. Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL April 2000.
7. Ocular injuries sustained during paintball: A recreational war game. **Mandava N**, Schwartz SD, Stout JT, Napoli J, Boucher MC, Yannuzzi L, 5th International Symposium on Ocular Trauma. Montreal, Canada July 2000.
8. Chimeric ribozyme to PCNA as a treatment for the prevention of fibrous proliferation in ocular diseases such as retinal detachment and trabeculectomy, **Mandava N,** Robbins J. FDA, August 2000.
9. Vitrectomy and scleral band for pseudophakic retinal detachment. **Mandava N,** Rodriguez-Coleman H, Schiff W, Barile GR. Vitreous Society, 2001.
10. Screening for diabetic retinopathy by primary care providers. Farley T, Carsky C, **Mandava N**, Parnes B. North American Primary Care Research Group, October 2003.
11. New instrument for sclerotomy depression. **Mandava N**, Rudometkin N, Olson JL, Ciardella A. Vail Vitrectomy, March 2007.
12. Self-reported perception of driving function following ranibizumab treatment in patients with neovascular AMD**. Mandava N**, Chang TS, Bressler NM. Macula Society. London, UK May 2007.
13. **Mandava N**, Korotkin A, Bennett JL, Olson JL, Quiroz-Mercado HQ. New Indications for Anti-VEGF Therapy: Retinal Arterial Macroaneurysm (RAM) and Nonarteritic Ischemic Optic Neuropathy (NAION) 31st Annual Macula Society Meeting, Palm Beach, Florida, January 2008.
14. **Mandava N**, Gilden D. Varicella Zoster Virus (VZV) antigen presence and distribution in Giant Cell Arteritis (GCA) positive temporal artery (TA) biopsies. American Society of Retinal Specialists, 2015.

**COURSES/LECTURES: (Invited)**

1. Wide angle viewing and liquid perfluorocarbons. Ophthalmology Grand Rounds, University of Colorado, Denver, CO November 2, 1998.
2. Current approaches to the treatment of ocular neovascularization. 3rd Annual Symposium, Department of Ophthalmology, University of Colorado, Denver, CO March 26-27, 1999.
3. Macular degeneration: Facts and future. Seniors’ Association, Denver Art Museum, Denver, CO May 1999.
4. Diabetic retinopathy and age-related macular degeneration. Family Practice Symposium, Estes Park, CO June 15-21, 1999.
5. Current treatments for angiogenesis in the eye/photodynamic therapy. Ophthalmology Grand Rounds, Porter Hospital, Denver, CO June 1999.
6. Diabetic retinopathy: Current management and case studies. Endocrinology Ground Rounds, University of Colorado, Denver, CO September 29, 1999.
7. Discussion of paper: Vitrectomy for ocular toxocariasis. Joint Meeting Pan American Association of Ophthalmology and American Academy of Ophthalmology, Orlando, FL October 24-27 1999.
8. Discussion of paper: Laser demarcation of subclinical retinal detachment. Joint Meeting Pan American Association of Ophthalmology and American Academy of Ophthalmology, Orlando, FL October 24-27 1999.
9. Diabetic vitrectomy. **Mandava N**, Petty S, Battle J, Instructional Course. Joint Meeting Pan American Association of Ophthalmology and American Academy of Ophthalmology, Orlando, FL October 24-27 1999.
10. Diabetic vitrectomy: Ophthalmology Grand Rounds, University of Colorado, Denver, CO November 3 1999.
11. Diabetic retinopathy and age-related macular degeneration. Family Practice Symposium, University of Colorado, Denver, CO November 4-9 1999.
12. Diabetic retinopathy: Update. 4th Annual Symposium, Department of Ophthalmology, University of Colorado, Denver, CO March 31-April 1 2000.
13. Experimental treatments for proliferative vitreoretinopathy. 4th Annual Symposium, Department of Ophthalmology, University of Colorado, Denver, CO March 31 – April 1 2000.
14. Decision making in the management of retinal detachment. Ophthalmology Grand Rounds, University of Colorado, Denver, CO November 1, 2000.
15. Diabetic retinopathy. Endocrinology Grand Rounds, Naomi Berrie Diabetes Center, Columbia University, New York, NY January 2001.
16. Advanced vitreoretinal surgical techniques and complications after cataract surgery course. Participant, Pan American Academy of Ophthalmology, Buenos Aires, Argentina July 21-25 2001.
17. Evolving techniques in vitreoretinal surgery. Faculty, Pan American Academy of Ophthalmology, Buenos Aires, Argentina July 21-25 2001.
18. New frontiers in the management of age-related macular degeneration. Faculty, Pan American Academy of Ophthalmology, Buenos Aires, Argentina July 21-25 2001.
19. Updated treatment of macular diseases. Co-coordinator, Pan American Academy of Ophthalmology, Buenos Aires, Argentina July 21-25 2001.
20. Current gene therapy in ophthalmology. 5th Annual Symposium, University of Colorado, Denver, CO September 21-22 2001.
21. Management of proliferative vitreoretinopathy – what’s on the horizon? 5th Annual Symposium, University of Colorado, Denver, CO September 21-22, 2001.
22. Age-related macular degeneration. Geriatric Grand Rounds, University of Colorado, Denver, CO December 6, 2001.
23. Pathobiology of proliferative vitreoretinopathy: Use of chimeric ribozyme for its treatment. Pathology Grand Rounds, University of Colorado, Denver, CO April 18, 2002.
24. Diabetic macular edema: Laser, surgery, pharmacotherapy. 6th Annual Symposium, University of Colorado, Denver, CO September 20-21, 2002.
25. Molecular therapies for retinal diseases. 6th Annual Symposium, University of Colorado, Denver, CO September 20-21, 2002.
26. New frontiers in the management of age-related macular degeneration. Participant, Pan American Academy of Ophthalmology, Orlando, FL October 20-23, 2002.
27. Liquid perfluorocarbons course. Faculty, Stanley Chang, et al. American Academy of Ophthalmology, Orlando, FL October 20-23, 2002.
28. Advances in vitreoretinal surgical techniques. Pan American Academy of Ophthalmology, San Juan, Puerto Rico March 28-April 1, 2003.
29. Diabetic macular edema: Laser, surgery, pharmacotherapy. Pan American Academy of Ophthalmology, San Juan, Puerto Rico March 28-April 1, 2003.
30. Diabetic macular edema and macular degeneration. JCAHPO meeting, Denver, CO May 4-9, 2003.
31. Diabetic macular edema: Laser, surgery, pharmacotherapy. 6th International Advanced Vitreoretinal Surgery Course, (IAVRSC), Chennai, India July 24-26, 2003.
32. Development of a chimeric ribozyme to treat PVR. Grand Rounds, LV Prasad Eye Institute, Hyderabad, India July 24-26, 2003.
33. Molecular therapies for retinal disorders. Faculty, 6th International Advanced Vitreoretinal Surgery Course (6th IAVRSC), Chennai, India July 24-26, 2003.
34. Gene therapy for proliferative vitreoretinopathy. Faculty, Retina Subspecialty Day, American Academy of Ophthalmology, Anaheim, CA November 15-17, 2003.
35. The Immusol Oligonucleotide Study: A new treatment of proliferative vitreoretinopathy? Retina Subspecialty Day, American Academy of Ophthalmology, Anaheim, CA November 15-17, 2003.
36. VIT100: for proliferative vitreoretinopathy. Faculty, 5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT), Monte Carlo, Monaco March 11-14, 2004.
37. Pharmacotherapy for proliferative vitreoretinopathy. Faculty, 8th Annual Symposium. University of Colorado, Denver, CO September 22-23, 2004.
38. Condiments in vitreoretinal surgery. Faculty, American Academy of Ophthalmology, New Orleans, LA October 23-26, 2004.
39. Pharmacology of intravitreal steroids. Age-related Macular Degeneration Symposium. Faculty, Pan American Congress of Ophthalmology. Santiago, Chile March 18-25, 2005.
40. New Developments in Diabetic Retinopathy Screening. Faculty, Pan American Congress of Ophthalmology. Santiago, Chile March 18-25, 2005.
41. Vitrectomy for Complex Diabetic Retinal Detachments. Faculty, Pan American Congress of Ophthalmology. Santiago, Chile March 18-25, 2005.
42. Pharmacotherapy for proliferative vitreoretinopathy: VIT100 study results. Faculty, 10th Annual Symposium. University of Colorado, Denver, CO September 22-23, 2005.
43. Condiments in vitreoretinal surgery. Faculty, American Academy of Ophthalmology, Chicago, IL October 15-18, 2005.
44. Pharmacotherapy for proliferative vitreoretinopathy. Faculty, Grand Rounds, LV Prasad Eye Institute. Hyderabad, India December 28, 2005.
45. VIT100 for proliferative vitreoretinopathy. Faculty, 6th Annual International Society for Ophthalmic Pharmaceuticals and Therapeutics, Berlin, Germany March 31-April 3, 2006.
46. Translation research: A key to the survival of the modern department of ophthalmology. Ophthalmology Grand Rounds. University of Colorado, Denver, CO June 2006.
47. Clinical implications of Anti-VEGF therapy in age-related macular degeneration. Faculty, 9th Annual Symposium. University of Colorado, Denver, CO September 2006.
48. New therapies in age-related macular degeneration. Faculty, Geriatrics Grand Rounds. University of Colorado, Denver, CO January 2007.
49. Age-related macular degeneration. Faculty, 11th Annual Symposium. University of Colorado, Denver, CO September 2007.
50. Anti-VEGF therapy for non-AMD retinal diseases. Faculty, Grand Rounds, University of Kentucky, Lexington, KY March 2008.
51. Proliferative Vitreoretinopathy: Development of VIT100. Faculty, Grand Rounds, University of Kentucky, Lexington, KY March 2008.
52. Update on Age-related macular degeneration. Faculty, Primary Care Physician Course, University of Colorado, Denver, CO June 2008.
53. Anti-VEGF therapy for non-AMD retinal disease. Faculty, 12th Annual Symposium. University of Colorado, Denver, CO September 2008.
54. Proliferative Vitreoretinopathy: Management in 2009. Faculty, Retina 2009, Mexico City, Mexico February 2009.
55. Anti-VEGF therapy for non-AMD retinal disease. Faculty, Retina 2009, Mexico City, Mexico February 2009.
56. Proliferative Vitreoretinopathy: Can we improve on outcomes? Faculty, 13th Annual Symposium. University of Colorado, Denver, CO October 2009.
57. Vitrectomy for epiretinal membrane: enzymatic vitreous digestion. Faculty, American Academy of Ophthalmology, San Francisco, CA October 2009.
58. Proliferative Vitreoretinopathy: A comprehensive review. Columbia University Ophthalmology Basic Science Course. Columbia University, College of Physician and Surgeons, New York, NY January 2010.
59. Anti-VEGF agents can cause glaucoma: Why? Ophthalmology Grand Rounds, Department of Ophthalmology, Columbia University, College of Physician and Surgeons, New York, NY January 2010.
60. High Molecular Weight Aggregates in Repackaged Bevacizumab. Faculty, 14th Annual Symposium. University of Colorado, Denver, CO October 2010.
61. High Molecular Weight Aggregates in Intravitreal Therapies. Retina Subspecialty Day, American Academy of Ophthalmology, Chicago, IL October 2010.
62. Nonretinal Complication of Intravitreal Therapies. Faculty, Grand Rounds, University of British Columbia, Vancouver, Canada May 2011.
63. Therapies for Proliferative Vitreoretinopathy. Faculty, Grand Rounds, University of British Columbia, Vancouver, Canada May 2011.
64. Nonretinal Complications of Intravitreal Therapies, Alumni Research Day Keynote, University of Florida. Jacksonville, FL June 2011
65. Antiangiogenic Therapy Perspectives. Faculty, 15th Annual Symposium. University of Colorado. Denver, CO October 2011.
66. Complications of Repackaged Ophthalmic Pharmacotherapies. American Association of Pharmaceutical Sciences, New Orleans, LA November 2011.
67. Nonretinal Complications of Intravitreal Therapy. Faculty, Johns Hopkins Current Concepts Meeting, Vail, CO. March 2012.
68. Pros and Cons of Hospital Based Systems.  Faculty, Association of the University Professors of Ophthalmology, San Diego, CA.  January 2013.
69. Innovation in Academic Departments of Ophthalmology.  Faculty, 17th Annual Symposium University of Colorado, Aurora, CO.  October 2013.
70. Nanoparticles for photovoltaic stimulation of the retina.  Faculty, Beckman Macular Degeneration Conference, Irvine, CA.  January 2014.
71. Translational research in academic departments of ophthalmology.  Faculty, Association of the University Professors of Ophthalmology, Key Largo, FL.  February 2014.
72. Acute retinal necrosis presenting with ischemic optic neuropathy and retinal vascular occlusive disease.  Faculty, Macula Society, San Diego, CA.  February 2014.
73. Nonretinal complications of intravitreal injection.  Faculty, Yale Retina symposium, Stamford, CT.  April 2014.
74. The future of age-related macular degeneration treatment.  Faculty, Yale Retina symposium, Stamford, CT.  April 2014.
75. The future of AMD therapy. University of Colorado, 18th annual symposium. September 2014.
76. Value of Innovation and translational research to the Department. Grand rounds SUNY Downstate. September 2014.
77. Nonretinal complications of intravitreal therapies. Grand rounds. SUNY downstate September 2014.
78. Photoactive quantum dots for retinal degenerations.  Beckman Macular Degeneration Meeting.  January 2015.
79. Developments in macular degeneration.  Aspen business luncheon.  January 2015.
80. Varicella Zoster Virus (VZV) antigen presence and distribution in Giant Cell Arteritis (GCA) positive temporal artery (TA) biopsies.  American Society of Retinal Specialists.  Vienna, Austria.  July 2015.
81. New Markers for Diabetic Retinopathy.  ADTC meeting (diabetes for primary care docs). Keystone, CO.  July 2015.
82. Translational Research in Academic Ophthalmology Departments. Keynote.  Duke Ophthalmology Alumni, Graduation meeting.  June 2016.
83. Nonretinal complications of anti-VEGF therapy in Diabetic Retinopathy. All India Diabetic Retinopathy Symposium. LV Prasad Eye Institute, Hyderabad, India. August 2016
84. Innovation in Ophthalmology Departments. Grand Rounds. University of California, San Diego. October 2016
85. Elucidating complications of anti-VEGF therapy. University of California, San Diego. October 2016
86. Building an Eye Care Network and Managing Quality and Risk. Association of the University Professors of Ophthalmology Annual Meeting. San Diego. January 2017

**ABSTRACTS/POSTERS: (Competitive)**

1. **Mandava N**, Donnenfeld ED, Grossman G, Mandava S. Topical antibiotic prophylaxis in cataract surgery: A rabbit endophthalmitis model. Association for Research in Vision and Ophthalmology Invest Ophthalmol Vis Sci 1996. (poster)
2. **Mandava N**, Chang S, Maberley D, Schiff W. Ciliary body damage as a predictive factor for outcomes after open-globe injury. American Academy of Ophthalmology November 1998. (poster)
3. **Mandava N**. Infrared optical properties of eye components and blood. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci May 2001. (poster)
4. Carlson IA, Manchester D, **Mandava N**, Bateman JB. Progressive Chorioretinal Degeneration and Cataracts in Seckel Syndrome. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci May 2004. (poster)
5. Morrisey M, **Mandava N**, Elias E, Bateman JB. Report of ocular features including retinal photoreceptor degeneration associated with a novel unbalanced chromosome translocation (6:12)(p21.1;p13) in an infant. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci May 2004. (poster)
6. Nguyen LT, Ciardella A, Braverman J, Taravella MJ, Davidson R, **Mandava N**. Microscope-induced retinal phototoxicity after cataract surgery measured by optical coherence tomography (OCT). Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci May 2004. (poster)
7. Kahook MY, Olson JL, **Mandava N**. Incidence of increased intraocular pressure after intravitreal triamcinolone acetonide injection. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci May 2005. (poster)
8. Doherty RS, Olson JL, **Mandava N**, Ciardella A. Clinical detection of macular edema in diabetic patients using the Automated Retinal Imaging System (ARIS). Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci May 2005. (poster)
9. Prall RF, **Mandava N**, Drack AV, Taylor M, Ku L. Ophthalmic manifestations of Danon Disease. American Academy of Ophthalmology October 2005. (poster)
10. Mackenzie DL, Kahook MY, Olson JL, **Mandava N**. Biometric and intraocular pressure evaluation of eyes post intravitreal triamcinolone acetonide and intravitreal pegaptanib injection. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci April 2006. (poster)
11. **Mandava N**, Prall R, Carsky C, Parnes B, Farley T. Screening for diabetic retinopathy in primary care using a non-mydriatic camera. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci April 2006. (poster)
12. Shah A, **Mandava N**, Olson JL. Three-way comparison of photodynamic therapy with and without adjunctive subtenon's or intravitreal triamcinolone acetonide in the treatment of choroidal neovascularization associated with age-related macular degeneration. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci April 2006. (poster)
13. Zimski L, Olson JL, **Mandava N**. Immune recovery uveitis associated with FK 506 (Tacrolimus) use after renal transplantation. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci April 2006. (poster)
14. Prall R, Drack A, Gregory D, Olson JL, Taylor M, **Mandava N**. Ophthalmic manifestations of Danon disease. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci April 2006. (poster)
15. Rudometkin NJ, Olson JL, Ciardella A, **Mandava N**. Initial fellow surgical efficiency and complications rates comparing 20 vs. 25 gauge vitrectomy. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci April 2006. (poster)
16. Gohel P, **Mandava N**, Olson JL. Vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci April 2006. (poster)
17. Olson JL, Courtney RJ, **Mandava N**. Intravitreal Anakinra Inhibits Growth of Choroidal Neovascular Membranes in an Animal Model. Combined Meeting of the Club Jules Gonin and The Retina Society, Cape Town, South Africa, October 2006. (poster)
18. **Mandava N**, Courtney RJ, Olson JL. Intravitreal Infliximab Inhibits Growth of Choroidal Neovascular Membranes in an Animal Model. Combined Meeting of the Club Jules Gonin and The Retina Society, Cape Town, South Africa, October 2006. (poster)
19. Kahook MY, Mackenzie DL, Faberowski N, Durairaj VD, **Mandava N**. Effect of Corneal Drying on Corneal Hysteresis Measurements Using the Ocular Response Analyzer. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci May 2007. (poster)
20. Rouhani B, **Mandava N**, Olson JL. Central retinal vein occlusion after intense exercise in five healthy patients. Association for Research in Vision and Ophthalmology, Invest Ophthalmol Vis Sci May 2007. (poster)
21. Olson JL, Courtney RJ, **Mandava N**. Intravitreal Anti-Fibroblast Agent in an Animal Model of Choroidal Neovascularization. American Society of Retinal Specialists, Maui, Hawaii, October 2008.
22. Guerrero-Naranjo JL, Salmon-de la Toba C, Velez-Montoya R, Garcia-Aguirre G, Martinez-Castellanos M, Luloh P, Annen M, Morales-CantonV , **Mandava N**, Quiroz-Mercado HQ. Cannulated Optic Nerve Implants Are Biocompatible in Pig Eyes: A New Drainage and Drug Delivery System 5963/A428 Association for Research in Vision and Ophthalmology (ARVO) 2008.
23. Pan CK, **Mandava N**, Oliver SC, Quiroz-Mercado HQ, Olson JL. Comparison of Concentration and Dosage of Intravitreal Recombinant IL-1 Receptor Antagonist in the Treatment of Choroidal Neovascular Membranes in a Rat Model. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2009.
24. Hendrick AM, **Mandava N**, Quiroz-Mercado HQ, Oliver SC, Pelak VS, Olson JL. Bevicizumab for Parry-Romberg Syndrome (PRS) Associated Optic Nerve Edema: An Optical Coherence Tomography (OCT) Case Report. . Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2009.
25. Courtney RJ, **Mandava N**, Oliver SC, Quiroz-Mercado HQ, Olson JL. Intravitreal Inhibition of CNV in an Animal Model: A Comparison of Infliximab, Anakinra and LD22-4. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2009.
26. Korotkin A, Quiroz-Mercado HQ, **Mandava N**, Olson JL, Oliver SC, Garcia G, Grinblat A. Vitreo-Retinal Dissector (VRD) for Pars Plana Vitrectomy. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2009.
27. Dixon JA, Olson JL, Durairaj VD, **Mandava N**. The Rate of Ptosis Following Subtenons Corticosteroid Injection. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2009.
28. Courtney RJ, **Mandava N**, Oliver SCN, Quiroz-Mercado HQ, Olson JL. Intravitreal Inhibition of CNV in an Animal Model: A Comparison of Infliximab, Anakinra and LD22-4. Association for Research in Vision and Ophthalmology, Poster #2964/A418, May 5, 2009.
29. Pan CK, **Mandava N**, Oliver SCN, Quiroz-Mercado HQ, Olson JL. Comparison of Concentration and Dosage of Intravitreal Recombinant IL-1 Receptor Antagonist in the Treatment of Choroidal Neovascular Membranes in a Rat Model. Association for Research in Vision and Ophthalmology, Poster #2971/A425, May 5, 2009.
30. Hendrick AM, **Mandava N**, Quiroz-Mercado HQ, Oliver SCN, Pelak VS, Olson JL. Bevicizumab for Parry-Romberg Syndrome (PRS) Associated Optic Nerve Edema: An Optical Coherence Tomography (OCT) Case Report. Association for Research in Vision and Ophthalmology, Poster #3261/A279, May 5, 2009.
31. Kupperman B, **Mandava N**. Vitreosolve for Enzymatic Vitreous Digestion. International Symposium on Ocular Pharmacology and Therapeutics (ISOPT), Rome, Italy, December 2009.
32. Horsley MB, Maycotte M, **Mandava N**, Kahook MY. Retinal Nerve Fiber Layer Thickness in Patients Receiving Long-Term Anti-VEGF Therapy. American Glaucoma Society Annual Meeting. Naples, FL. March 3-7, 2010.
33. Seibold LK, **Mandava N,** Kahook MY. Comparison of Spectral Domain Retinal Nerve Fiber Layer Thickness and Agreement with Time Domain Optical Coherence Tomography. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2010.
34. Stafeeva K, Pan C, Patel CC, Olson JL, **Mandava N**, Oliver SC, Quiroz-Mercado HQ. Importance of Fundus Autofluorescence (FAF) in a Series of Misdiagnosed Cases Involving Choroidal, RPE, and Retinal Pathology. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2010.
35. Ammar DA, Liu L, Ruzycki P, **Mandava N**, Carpenter J, Petrash JM, Kahook MY. High Molecular Weight Aggregates in Repackaged Bevacizumab. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2010.
36. Olson JL, **Mandava N**. Intraocular Photoactive Quantum Dots in a Rodent Model of Progressive Photoreceptor Degeneration. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2010.
37. McCourt EA, Hink EM, Olson JL, **Mandava N**, Durairaj VD, Oliver SC. Isolated Group B Streptococcal Endogenous Endophthalmitis Simulating Retinoblastoma in a Healthy Full Term Infant. Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2010.
38. Patel CC, **Mandava N**, Quiroz-Mercado HQ, Oliver SC, Braverman RS, Olson JL. Treatment of Intractable Posterior Uveitis in Pediatric Patients with the Fluocinolone Acetonide Intravitreal Implant (Retisert). Association for Research in Vision and Ophthalmology, Annual Meeting Fort Lauderdale, May 2010.
39. Ammar DA, Liu L, Ruzycki P, **Mandava N**, Carpenter J, Petrash JM, Kahook MY. High Molecular Weight Aggregates in Repackaged Bevacizumab. Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida. May 2-6, 2010.
40. Seibold LK, **Mandava N**, Kahook MY. Comparison of Spectral Domain Retinal Nerve Fiber Layer Thickness and Agreement with Time Domain Optical Coherence Tomography, Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida. May 2-6, 2010.
41. Pan CK, Durairaj VD, Kompella UB, Agwu O, Oliver SCN, Quiroz-Mercado HQ, **Mandava N**, Olson JL. Comparison of Long-Acting Bevacizumab Formulations in the Treatment of Choroidal Neovascularization in a Rat Model. Association for Research in Vision and Ophthalmology, Poster #2457/D1053, May 3, 2010.
42. Quiroz-Mercado HQ, Patel CC, Oliver SCN, Olson JL, **Mandava N**. 25 Gauge Plus Vitrector in Lieu of Vitreoretinal Forceps for Epiretinal Membrane and Internal Limiting Membrane Peeling. Association for Research in Vision and Ophthalmology, Poster #1763/A469, May 3, 2010.
43. Mathias MT, Oliver SCN, Olson JL, **Mandava N**, Quiroz-Mercado HQ, Pichi F, Torrazza C, Ciardella A. Retinal Phototoxicity: Possible Association with Chandelier Endoillumination. Association for Research in Vision and Ophthalmology, Poster #3614/A183, May 4, 2010.
44. Seibold LK, **Mandava N**, Kahook MY. The Effect of Software Upgrade on Optical Coherence Tomography Measurement of Retinal Nerve Fiber Layer Thickness. American Glaucoma Society Annual Meeting. Dana Point, CA March 5, 2011.
45. Velez-Montoya R, Olson JL , Petrash JM, Messersmith W, **Mandava N**, Oliver SCN. Acute Onset Central Serous Retinopathy in Association with MEK Inhibitor Use for Metastatic Cancer. 2011 Pan-American Research Day, Association for Research in Vision and Ophthalmology. Paper Presentation, April 30, 2011
46. Patel CC, **Mandava N**, Oliver SCN, Quiroz-Mercado HQ, Olson JL. A Comparison of Membrane Peeling Forces Created by 20, 23, and 25 Gauge Intraocular Forceps. Association for Research in Vision and Ophthalmology, Poster #537/A277, May 1, 2011.
47. Mathias MT, Quiroz-Mercado HQ, **Mandava N**, Oliver SCN, Olson JL. Combination Bevacizumab and Grid Pattern Focal Laser Using a Minimum of 900 Sub-Threshold Spots for Diabetic Macular Edema. Association for Research in Vision and Ophthalmology, Poster #587/A327, May 1, 2011.
48. Stafeeva K, Oliver SCN, **Mandava N**, Quiroz-Mercado HQ, Olson JL. Pan-Ocular Argyrosis from Chronic Silver Nitrate Salt Ingestion. Association for Research in Vision and Ophthalmology, Poster #1036/A438, May 1, 2011.
49. Velez-Montoya R, Olson JL , Petrash JM, Messersmith W, **Mandava N**, Oliver SCN. Acute Onset Central Serous Retinopathy in Association with MEK Inhibitor Use for Metastatic Cancer. Association for Research in Vision and Ophthalmology, Poster #2153/A123, May 2, 2011.
50. McCourt EA, Oliver SCN, Kahook MY, **Mandava N**. Subfoveal Choroidal Thickness in Age Related Macular Degeneration. Association for Research in Vision and Ophthalmology, Poster #3532/A330, May 3, 2011.
51. Seibold LK, **Mandava N**, Kahook MY. Retinal Nerve Fiber Layer Thickness Measurements after Optical Coherence Tomography Software Upgrade. Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida. May 3, 2011.
52. Ernst BJ, Oliver SCN, Quiroz-Mercado HQ, **Mandava N**, Olson JL. Evaluation of Dropped Foreign Bodies in Saline Compared to Perfluorocarbon Liquid. Association for Research in Vision and Ophthalmology, Poster #537/A277, May 5, 2011.
53. Mathias MT, Quiroz-Mercado HQ, Velez-Montoya R, **Mandava N**, Oliver SC, Olson JL. Combination Bevacizumab and Grid Pattern Focal Laser Using a Minimum of 900 Sub- Threshold Spots For Diabetic Macular Edema. Association for Research in Vision and Ophthalmology (ARVO) 2011.
54. Velez-Montoya R, Olson JL, Petrash JM, Messersmith W, **Mandava N**, Oliver SC. Acute Onset Central Serous Retinopathy In Association With Mek Inhibitor Use For Metastatic Cancer. Association for Research in Vision and Ophthalmology (ARVO) 2011.
55. Oliver SCN, Velez-Montoya R, Messersmith W, Olson JL, Petrash JM, **Mandava N.** MEK Inhibitor-Associated Serous Retinopathy – Clinical Features of a New Retinal Disorder. Poster Presentation, International Congress of Ocular Oncology 2011, Buenos Aires, Argentina, November 16, 2011.
56. Bhandari R, Mathias MT, Ernst BJ, Schwartz S, Olson JL, Oliver SCN, **Mandava N**, Quiroz-Mercado HQ. Combination Bevacizumab and Comprehensive Grid Subthreshold Laser Using a Minimum of 900 Spots as Compared to Bevacizumab Alone for Treatment of Diabetic Macular Edema. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL. Poster #395/D946, May 6, 2012.
57. Schwartz S, Baldivieso V, Sabel AL, **Mandava N**, Oliver SCN, Olson JL, Quiroz-Mercado HQ. Non-Mydriatic Single Field Fundus Camera For Diabetic Retinopathy Screening: Assessment of Efficacy, Prevalence and Risk Factors in a Safety Net Institution. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL. Poster #2891/A318, May 8, 2012.
58. Velez-Montoya R, **Mandava N**, Stoldt CR, Olson JL. Quantum Dots As Neuroprotective Factor In A Model Of Retinal Photoreceptor Degeneration. Association for Research in Vision and Ophthalmology (ARVO) 2012.
59. Bhandari R, Velez-Montoya R, Oliver SC, Ernst BJ, Olson JL, Quiroz-Mercado HQ, **Mandava N**. Aflibercept for active choroidal neovascularization with poor clinical response to standard anti-VEGF treatment. American Society of Retina Specialists Congress 2012, Las Vegas, USA.
60. Quiroz-Mercado HQ, Bhandari R, Schwartz S, Olson JL, Oliver SC, **Mandava N**, Velez-Montoya R, Mathias MT. Small gauge direct silicone oil (SO) perfluoro-n-octane (PFO) interchange. Comparison of two methods: use of chandelier light (CHL) and use of viscous fluid infusion cannula (VFIC). Association for Research in Vision and Ophthalmology (ARVO) Seattle 2013.
61. Schwartz S, Oliver SCN, Victoria R, Bhandari R, **Mandava N**, Mercado HQ. Assessment of retinal perfusion using ultra wide filed (UWF) imaging in patients with diabetic retinopathy treated with intravitreal bevacizumab (IVB). Association for Research in Vision and Ophthalmology, Seattle, WA. Poster #199 - D0010. May 5, 2013.
62. Faberowski N, Mercado HQ, Gonzales C, Bhandari R, Oliver SCN, Olson JL, **Mandava N**, Schwartz S. Retina evaluation with non mydriatic ultra wide field color imaging after cataract surgeries in asymptomatic patients. Association for Research in Vision and Ophthalmology, Seattle, WA. Poster #2997 - C0088. May 7, 2013.
63. Mercado HQ, Bhandari R, Schwartz S, Olson JL, Oliver SCN, **Mandava N**, Velez-Montoya R, Mathias MT. Small gauge direct silicon oil (SO) perfluoro-n-octane (PFO) interchange. Comparison of two methods: use of chandelier light (CHL) and use of viscous fluid infusion cannula (VFIC) Association for Research in Vision and Ophthalmology, Seattle, WA. Poster #2875 - B0184. May 7, 2013.
64. Kim YC, Harasawa M, Villanueva G, Siringo FS, Paciuc-Beja M, Olson JL, **Mandava N**, Quiroz-Mercado HQ. Enhanced High-density Line Spectral-domain Optical Coherence Tomography Imaging of Vitreoretinal Interface. Description of Selected Cases. Association for Research in Vision and Ophthalmology, Annual Meeting, Denver, May 2015.
65. Siringo FS, Jeffrey JL, Oliver SC, Mathias MT, **Mandava N**, Smith JM. Tobacco Use as a Risk Factor for Proliferative Vitreoretinopathy. Association for Research in Vision and Ophthalmology, Annual Meeting, Denver, May 2015.